Phacilitate Leaders Forum

Phacilitate Leaders Europe Agenda 2018

Loading

Panel: Viral vectors (Lenti, Retro, AAV, & gene transfer) Vs. their non-viral alternatives

11-Sep-2018
Getting technical - Cell & Gene Therapy Europe
  • A one hour debate which includes a case study from each side - audience questions and involvement is encouraged.
  • Would non-viral vector approaches and DNA approaches get us past the challenges we are encountering with viral vectors? COGs, re-dosing, quality for GMP supply at commercial scale- surviving the regulators, capacity etc.
  • Can we get good enough gene integration to shorten the process? Can we transfect/transduce and go straight into the patient without the need to expand cells to greatly reduce time and cost, risk of contamination, cell exhaustion etc.
Speakers
Branden Moriarity, CSO - B-MoGen
Janneke Meulenberg, COO - Arthrogen
Michael Maguire, CEO - Avectas
Ruth McDermott, Platform Manager - Regenerative Medicine
Testimonials
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Jean-Philippe Combal
    GenSight Biologics
  • The conference consistently proves to be a great forum for networking with industry leaders in the development of cellular and gene therapies as well as vendors for important technologies and services.
    Michael Covington
    Juno Therapeutics, Inc
  • It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance
    Bertrand Alexandre
    Celyad
  • Phacilitate EU delivered it's promise and more, the topics discussed were highly relevant, with very good and professional speakers and panelists. You will see me next year in Berlin.
    Dr Ohad Karnieli
    Karnieli Ltd